Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence

C Sardu, J Gambardella, MB Morelli, X Wang… - Journal of clinical …, 2020 - mdpi.com
The symptoms most commonly reported by patients affected by coronavirus disease (COVID-
19) include cough, fever, and shortness of breath. However, other major events usually …

Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms

A Mafficini, A Scarpa - Endocrine reviews, 2019 - academic.oup.com
Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are heterogeneous
regarding site of origin, biological behavior, and malignant potential. There has been a rapid …

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2–related disease

M Suárez-Fariñas, M Tokuyama, G Wei, R Huang… - Gastroenterology, 2021 - Elsevier
Background and Aims The presence of gastrointestinal symptoms and high levels of viral
RNA in the stool suggest active severe acute respiratory syndrome coronavirus 2 (SARS …

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

P Cejas, Y Drier, KMA Dreijerink, LAA Brosens… - Nature medicine, 2019 - nature.com
Most pancreatic neuroendocrine tumors (PNETs) do not produce excess hormones and are
therefore considered 'non-functional',–. As clinical behaviors vary widely and distant …

Alterations in beta cell identity in type 1 and type 2 diabetes

ASM Moin, AE Butler - Current diabetes reports, 2019 - Springer
Abstract Purpose of Review To discuss the current understanding of “β cell identity” and
factors underlying altered identity of pancreatic β cells in diabetes, especially in humans …

[HTML][HTML] Combined inhibition of DYRK1A, SMAD, and trithorax pathways synergizes to induce robust replication in adult human beta cells

P Wang, E Karakose, H Liu, E Swartz, C Ackeifi… - Cell metabolism, 2019 - cell.com
Small-molecule inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) induce
human beta cells to proliferate, generating a labeling index of 1.5%–3%. Here, we …

The human islet: mini-organ with mega-impact

JT Walker, DC Saunders, M Brissova… - Endocrine …, 2021 - academic.oup.com
This review focuses on the human pancreatic islet—including its structure, cell composition,
development, function, and dysfunction. After providing a historical timeline of key …

DYRK1A inhibitors as potential therapeutics for β-cell regeneration for diabetes

K Kumar, C Suebsuwong, P Wang… - Journal of Medicinal …, 2021 - ACS Publications
According to the World Health Organization (WHO), 422 million people are suffering from
diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose …

β-cell fate in human insulin resistance and type 2 diabetes: a perspective on islet plasticity

T Mezza, F Cinti, CMA Cefalo, A Pontecorvi… - Diabetes, 2019 - Am Diabetes Assoc
Although it is well established that type 2 diabetes (T2D) is generally due to the progressive
loss of β-cell insulin secretion against a background of insulin resistance, the actual …

GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration

C Ackeifi, P Wang, E Karakose… - Science translational …, 2020 - science.org
Glucagon-like peptide-1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 inhibitors are
widely prescribed diabetes drugs due to their ability to stimulate insulin secretion from …